Use this URL to cite or link to this record in EThOS: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.779067
Title: Synergistic treatment of lung cancer with genetically modified cell therapy and chemotherapy
Author: Kolluri, K. K.
ISNI:       0000 0004 7964 7674
Awarding Body: UCL (University College London)
Current Institution: University College London (University of London)
Date of Award: 2016
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Please try the link below.
Access from Institution:
Abstract:
Lung cancer and malignant pleural mesothelioma (MPM) carry a high mortality. Conventional therapies are ineffective in their treatment and there is a need to develop novel therapies. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a pro-apoptotic agent that triggers the extrinsic death pathway selectively in cancer cells. Mesenchymal stem cells (MSCs) are a type of bone marrow-derived stem cell that have been widely shown to home to and to infiltrate areas of the tumour microenvironment. This homing capacity can be exploited to deliver pro-apoptotic agents, including TRAIL, straight into the tumour micro-environment. Earlier studies show cancers can be treated with TRAIL-expressing MSCs (MSC-flT cells). However, some cell lines are resistant to MSC-flT cells. This study aimed to increase the efficiency of tumour cell killing using MSCs that are engineered to express TRAIL. This study investigates if cancer cell-killing by MSC-flT cells could be enhanced for the treatment of TRAIL-resistant cancers. The aims of this study were to increase the tumour cell-killing efficiency of MSCs engineered to express TRAIL by identifying whether the full-length or soluble form of TRAIL expressed by MSCs is superior in tumour cell killing, whether cancer cell-killing by MSC-flT cells can be increased by combining them with novel chemotherapeutic agents and to identify a biomarker to predict sensitivity to TRAIL. Cancer cell-killing by MSCs expressing full-length TRAIL was superior to that of MSCs expressing the shortened soluble form of TRAIL. MSC-flT cells showed a synergistic cancer killing affect when combined with novel chemotherapeutic agents. In collaboration with McDermott's laboratory in the Wellcome Trust Sanger Institute, it was found that BAP1-mutated MPM cells are sensitive to TRAIL. This was validated by knock-in and knockdown experiments. It was shown that BAP1-mutated tumours are sensitive to TRAIL in vivo. Further work was done to delineate the mechanism of BAP1-induced TRAIL resistance. The deubiquitinating function of BAP1 and its nuclear localization were shown to be required for TRAIL resistance. This indicates that loss of function of BAP1 is a biomarker for TRAIL sensitivity.
Supervisor: Janes, S. M. ; Morris, E. Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.779067  DOI: Not available
Share: